Merck & Co., Inc. (NYSE: MRK) is one of the. The company announced that the US FDA approved ENFLONSIA™ (clesrovimab-cfor) for ...

The ACIP is recommending the use of Enflonsia for the prevention of RSV lower respiratory tract disease in infants younger than 8 months.

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

An outside group of experts agreed that the CDC should recommend a new antibody drug that offers protection against RSV for ...

U.S. Health Secretary Robert F. Kennedy Jr.'s newly revamped vaccine advisory panel voted on Thursday to recommend Americans ...

Enjoy, and see you soon… A fast-growing group of Americans is turning to what many call the “gray market” for obesity ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

CDC panel backs Merck's Enflonsia for RSV prevention in infants; FDA-approved therapy reduced hospitalizations by 84% in ...

A startling new vision of vaccination in America is becoming clearer — one likely to involve fresh scrutiny of established science and practices, and limits on vaccines that have been studied for ...

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

The votes on vaccine recommendations are the first move by the panel after Health and Human Services Secretary Robert F.

The Trump administration’s new vaccine advisers endorsed this fall’s flu vaccines for just about every American but threw in ...